Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Inclusion Criteria

• •Subjects who meet clinical criteria for schizophrenia or schizo-affective disorder utilizing the structured clinical interview (SCI)
• •Must be treated with a second generation anti-psychotic drug other than clozapine at a stable dose for at least 4 weeks and must have been on that drug and clinically stable for at least 8 weeks
• •Must have no more than "moderate" severity rating for negative symptoms: BPRS item ≤4
• •A minimal level of extrapyramidal symptoms (EPS); Simpson-Angus Scale total score ≤6
• •A minimal level of depression; Calgary Depression Scale total score ≤10
• •Must have a general health status acceptable for participation in a 12-week clinical trial
• •Fluency (oral and written) in the language in which the standardized tests will be administered
• •If a smoker, the ability to refrain from smoking for at least 30 minutes prior to any cognitive testing